$840 Million is the total value of Sarissa Capital Management LP's 11 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALKS | Sell | ALKERMES PLC | $234,246,043 | -25.3% | 8,964,640 | -36.1% | 27.88% | -21.3% |
| IRWD | IRONWOOD PHARMACEUTICALS INC | $203,072,100 | +19.6% | 16,390,000 | 0.0% | 24.17% | +25.9% | |
| BIIB | BIOGEN INC | $178,059,560 | +3.7% | 643,000 | 0.0% | 21.19% | +9.2% | |
| GILD | Sell | GILEAD SCIENCES INC | $91,752,188 | +16.8% | 1,068,750 | -16.1% | 10.92% | +23.0% |
| INVA | INNOVIVA INC | $87,635,500 | +14.1% | 6,614,000 | 0.0% | 10.43% | +20.2% | |
| MRSN | MERSANA THERAPEUTICS INC | $23,422,479 | -13.3% | 3,997,010 | 0.0% | 2.79% | -8.7% | |
| BCRX | Sell | BIOCRYST PHARMACEUTICALS INC | $11,253,706 | -35.8% | 980,288 | -29.5% | 1.34% | -32.4% |
| AMRN | Sell | AMARIN CORP PLCspons adr new | $5,816,470 | -77.8% | 4,807,000 | -80.0% | 0.69% | -76.6% |
| VOR | VOR BIOPHARMA INC | $4,109,700 | +67.1% | 618,000 | 0.0% | 0.49% | +75.9% | |
| PEAR THERAPEUTICS INC | $590,420 | -42.2% | 500,356 | 0.0% | 0.07% | -39.1% | ||
| REGULUS THERAPEUTICS INC | $253,701 | -19.5% | 185,183 | 0.0% | 0.03% | -16.7% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC. | 32 | Q3 2023 | 37.1% |
| INNOVIVA INC. | 29 | Q3 2023 | 19.5% |
| IRONWOOD PHARMACEUTICALS INC. | 24 | Q3 2023 | 24.2% |
| ABBVIE INC. | 23 | Q2 2020 | 24.4% |
| MEDICINES CO. | 20 | Q4 2019 | 33.9% |
| MERSANA THERAPEUTICS INC. | 19 | Q3 2023 | 7.9% |
| ALKERMES PLC | 16 | Q3 2023 | 43.7% |
| INTERCEPT PHARMACEUTICALS INC. | 15 | Q2 2021 | 10.7% |
| BIOCRYST PHARMACEUTICALS INC | 14 | Q3 2023 | 7.4% |
| VIVUS INC | 14 | Q1 2017 | 8.8% |
View Sarissa Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Alkermes plc. | August 24, 2023 | 8,323,400 | 5.0% |
| Innoviva, Inc. | May 15, 2023 | 6,904,000 | 10.5% |
| IRONWOOD PHARMACEUTICALS INC | March 01, 2021 | 14,890,000 | 9.3% |
| Iterum Therapeutics plcSold out | February 12, 2021 | 0 | 0.0% |
| BIOCRYST PHARMACEUTICALS INC | January 25, 2021 | 8,844,000 | 5.0% |
| Mersana Therapeutics, Inc. | January 25, 2021 | 3,770,000 | 5.5% |
| MEDICINES CO /DESold out | January 07, 2020 | 0 | 0.0% |
| Regulus Therapeutics Inc. | January 03, 2020 | 7,935,322 | 29.4% |
| NOVELION THERAPEUTICS INC. | November 09, 2018 | 909,296 | 4.6% |
| APRICUS BIOSCIENCES, INC. | September 05, 2018 | 1,152,455 | 4.8% |
View Sarissa Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-03-19 |
| 13F-HR | 2024-02-14 |
| 4 | 2023-12-19 |
| SC 13D/A | 2023-12-05 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-19 |
| SC 13D/A | 2023-09-05 |
| SC 13D/A | 2023-08-24 |
| 13F-HR | 2023-08-14 |
| DFAN14A | 2023-06-28 |
View Sarissa Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.